ALS-I（Cat No.:I021844）is a small-molecule inhibitor designed to target key pathological pathways associated with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease affecting motor neurons. While the specific mechanism of ALS-I may vary by study, such compounds typically aim to reduce neuroinflammation, oxidative stress, glutamate excitotoxicity, or protein misfolding—hallmarks of ALS pathology. ALS-I is commonly used in preclinical models to evaluate its neuroprotective effects, delay in motor neuron degeneration, and functional improvement. It serves as a valuable research tool in the ongoing search for disease-modifying therapies for ALS.